Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR LANOXIN PEDIATRIC


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lanoxin Pediatric

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Abbott Medical Devices N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Duke Clinical Research Institute N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed St. Jude Medical N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Mayo Clinic N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lanoxin Pediatric

Condition Name

Condition Name for Lanoxin Pediatric
Intervention Trials
Healthy 7
Atrial Fibrillation 2
Arrhythmia 1
Pharmacokinetics 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lanoxin Pediatric
Intervention Trials
Atrial Fibrillation 2
Heart Failure 1
Chemical and Drug Induced Liver Injury 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lanoxin Pediatric

Trials by Country

Trials by Country for Lanoxin Pediatric
Location Trials
United States 19
Sweden 1
China 1
Germany 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lanoxin Pediatric
Location Trials
Texas 2
Connecticut 2
Illinois 2
California 2
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lanoxin Pediatric

Clinical Trial Phase

Clinical Trial Phase for Lanoxin Pediatric
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
Phase 1 11
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lanoxin Pediatric
Clinical Trial Phase Trials
Completed 13
Recruiting 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lanoxin Pediatric

Sponsor Name

Sponsor Name for Lanoxin Pediatric
Sponsor Trials
AstraZeneca 2
Bristol-Myers Squibb 2
Achillion, a wholly owned subsidiary of Alexion 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lanoxin Pediatric
Sponsor Trials
Industry 16
Other 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
Medtronic
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.